Davis Polk Reps Oracle In $685M Phase Forward Deal

Law360, New York (April 16, 2010, 1:46 PM EDT) -- Technology giant Oracle Corp. announced Friday that it would acquire medical clinical research software developer Phase Forward Inc. for $17 per share, or approximately $685 million.

Waltham, Mass.-based Phase Forward said Friday that its software had been deployed in over 10,000 clinical trials and also was used by hundreds of corporate customers to accelerate innovation in drug development and patient care.

The company's software manages clinical development and safety processes from phase I clinical trials through regulatory submission and post-approval monitoring.

The $17 per share price...
To view the full article, register now.